MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism dementia complex(PDC)"

  • 2025 International Congress

    Unveiling a rare case: Novel TBK1 variant presenting as Multiple system atrophy-like phenotype

    R. Kandadai, M. Karri, S. Kola, R. Borgohain, R. Alugolu, P. Vvsrk, A. Nalamasa (Hyderabad, India)

    Objective: Tumour necrosis factor NF-ƘB activator (TANK) binding kinase 1 (TBK1) is necessary for immune and inflammatory responses. Reports of TBK1 with neurodegeneration are noted…
  • 2025 International Congress

    Impaired glymphatic clearance independently contributes to poor outcomes in Parkinson’s disease

    A. Zarkali, G. Thomas, R. Paterson, N. Hannaway, I. Dobreva, A. Heslegrave, E. Veleva, H. Zetterberg, R. Weil (London, United Kingdom)

    Objective: Clarify how glymphatic clearance impacts cognition in PD and its interaction with established imaging markers. Background: Impaired glymphatic clearance may contribute to pathological accumulations…
  • 2025 International Congress

    Prevalence and Clinical Characteristics of Parkinson’s disease in Rural Nepal: A Community-Based Cross-Sectional Study

    A. Chandra, A. Chandra, S. Acharya (Kathmandu, Nepal)

    Objective: This study aims to determine the prevalence of PD in rural Nepal and characterize its clinical features in an effort to bridge the gap…
  • 2025 International Congress

    Patients’ Perspective on Screening for Non-Motor Symptoms in Parkinson’s Disease, A QI Project

    C. Flavin, G. Lamotte, P. Moretti (Salt Lake City, USA)

    Objective: To assess deficiencies in patient care for individuals with Parkinson's disease in neurology clinics, with a particular focus on nonmotor symptoms. Background: While motor…
  • 2025 International Congress

    Beyond Motor Symptoms: The Interplay Between Non-Motor Symptoms and Caregiver Challenges in Late-Stage Parkinson’s Disease

    D. Shah, A. Kothiala, D. Christian (Ahmedabad, India)

    Objective: To assess the relationship of non-motor (neuropsychiatric (NPS)) symptoms with the severity of motor symptoms of Parkinson’s Disease (PD). And to study the impact…
  • 2024 International Congress

    Parkinsonism due to Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Responsive to Carbidopa/Levodopa

    P. Hoff, F. Butt (Oklahoma City, USA)

    Objective: To describe a case of Parkinsonism due to ALSP which is responsive to carbidopa/levodopa Background: Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)…
  • 2024 International Congress

    Misdiagnosis of Cognitive Impairment in Parkinson’s disease

    F. Rodriguez-Porcel, T. Turner (Charleston, USA)

    Objective: We explored potential bias to diagnose cognitive impairment in People with Parkinson’s (PwP) followed in the Parkinson’s Progressive Markers Initiative (PPMI). Background: In primary…
  • 2024 International Congress

    Genome-wide Survival Analysis Identified Association Between HS1BP3 and APOE loci and Dementia in Parkinson’s disease

    S. Jo, J-H. Oh, J. Lee, S. Son, CO. Sung, SJ. Chung (Seoul, Republic of Korea)

    Objective: We aim to conduct a genome-wide survival study (GWSS) to identify single nucleotide polymorphisms (SNP) associated with dementia in Parkinson’s disease (PD) with a…
  • 2023 International Congress

    How does a diagnosis of Dementia with Parkinson’s influence future care provision?

    B. Mohamed, A. Rafeeq, J. Adenwalla, C. Thomas, S. Page, R. Lewis-Morton, T. Williams, S. Mahon (cardiff, United Kingdom)

    Objective: To describe the trajectory of Parkinson’s after the onset of dementia including setting of care, frailty levels and mortality rate. Background: Cardiff and Vale…
  • 2023 International Congress

    A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.

    S. Pasternak, C. Silveira, K. Coleman, R. Garcia, J. Wells, M. Borrie, P. Macdonald, R. Bartha, M. Jenkins, S. Morrow, D. Mendonca, G. Zou, E. Finger, T. Rupar, R. Tirona, M. Jog (London, Canada)

    Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley